1-3 of 3
Eckhart Weidmann, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Mathias J Rummel, MD, PhD, Aline Tenzer, Norbert Niederle, MD, PhD, Chrisoph Losem, MD, PhD, Christina Balser, MD, PhD, Harald-E. Balló, MD, PhD, Manfred Welslau, MD, PhD, Ulrich von Grünhagen, MD, PhD, Wolfram Brugger, MD, PhD, Georg Maschmeyer, MD, PhD, Axel C. Matzdorff, MD, PhD, Arnold Ganser, MD, PhD, Eckhart Weidmann, MD, PhD, Gerhard Heil, MD, PhD, Axel Hinke, Jürgen Barth
Journal: Blood
Blood (2010) 116 (21): 3090.
https://doi.org/10.1182/blood.V116.21.3090.3090
Published: 2010
Journal Articles

A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, STefan W. Krause, MD, PhD, Marion Subklewe, MD, Judith Kruse, MD, Martin Soekler, MD, Katja Weisel, MD, Soo-Zin Kim, MD, Martin H. Dreyling, MD, PhD, Elke Jager, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2721.
https://doi.org/10.1182/blood.V108.11.2721.2721
Published: 2006
Journal Articles

Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.

Eckhart Weidmann, MD, PhD, Georg Hess, MD, Stefan W. Krause, MD, PhD, Holger Hebart, MD, PhD, Martin Dreyling, MD, PhD, Marion Subklewe, MD, Christine Falge, MD, Kai U. Chow, MD, PhD, Elke Jaeger, MD, PhD, Parisis S. Mitrou, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 2640.
https://doi.org/10.1182/blood.V104.11.2640.2640
Published: 2004